Elekta AB (publ) (EKTAY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Elekta AB (publ) (EKTAY) trades at $6.31 with AI Score 47/100 (Weak). Elekta AB (publ) is a Swedish medical technology company specializing in clinical solutions for cancer and brain disorders. Market cap: 3B, Sector: Healthcare.
Last analyzed: Mar 15, 2026Elekta AB (publ) (EKTAY) Healthcare & Pipeline Overview
Elekta AB (publ) provides radiotherapy and neurosurgery solutions, including advanced treatment delivery systems and software. With a global presence, Elekta focuses on precision radiation medicine, competing with companies offering similar technologies for cancer and brain disorder treatments, while navigating regulatory landscapes and technological advancements.
Investment Thesis
Elekta AB (publ) presents a mixed investment case. The company's established position in radiation therapy and neurosurgery provides a stable revenue base. A dividend yield of 4.28% may attract income-focused investors. However, a negative profit margin of -0.2% and a high P/E ratio of -549.61 raise concerns about profitability. Growth catalysts include expanding the installed base of Elekta Unity MR-Linac systems and increasing software and service revenue. Potential risks include competition from established players and the capital-intensive nature of the medical technology industry. Investors should carefully weigh these factors before considering an investment in EKTAY.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $2.24 billion reflects Elekta's position in the medical technology sector.
- Dividend yield of 4.28% offers a potential income stream for investors.
- Gross margin of 37.5% indicates the profitability of Elekta's products and services before operating expenses.
- Beta of 1.09 suggests that EKTAY's stock price is slightly more volatile than the overall market.
- Negative profit margin of -0.2% signals challenges in achieving profitability.
Competitors & Peers
Strengths
- Established market position in radiation therapy and neurosurgery.
- Comprehensive product portfolio.
- Global presence and distribution network.
- Strong brand reputation.
Weaknesses
- Negative profit margin.
- High P/E ratio.
- Dependence on capital equipment sales.
- Exposure to currency fluctuations.
Catalysts
- Ongoing: Continued adoption of Elekta Unity MR-Linac systems by cancer centers.
- Upcoming: Publication of clinical data demonstrating the efficacy of Elekta's solutions in treating cancer and brain disorders (expected Q4 2026).
- Ongoing: Expansion of Elekta's software and service offerings.
- Upcoming: Regulatory approvals for new products and technologies in key markets (expected H1 2027).
Risks
- Potential: Competition from established players in the radiation therapy and neurosurgery markets.
- Potential: Technological obsolescence.
- Ongoing: Regulatory changes and compliance requirements.
- Ongoing: Economic downturns and healthcare spending constraints.
- Potential: Currency fluctuations.
Growth Opportunities
- Expansion of Elekta Unity MR-Linac: Elekta Unity, an MR-Linac system, offers real-time imaging during radiation therapy. Increasing the installed base of Elekta Unity systems represents a significant growth opportunity. The market for MR-Linac systems is projected to reach $500 million by 2028. Elekta's competitive advantage lies in its integrated hardware and software platform.
- Growth in Software and Service Revenue: Elekta's software and service offerings, including MOSAIQ Plaza and Elekta Axis Cloud, provide recurring revenue streams. The market for oncology information systems is expected to reach $4 billion by 2027. Elekta's focus on integrated solutions and data analytics positions it for growth in this area.
- Emerging Markets Expansion: Expanding into emerging markets, such as China and India, offers significant growth potential. The demand for advanced cancer treatment solutions is increasing in these regions due to rising cancer incidence and improving healthcare infrastructure. Elekta's global presence and established distribution network provide a competitive advantage.
- Innovation in Neurosurgery: Elekta's Leksell Gamma Knife remains a leading solution for non-invasive brain surgery. Continued innovation in neurosurgery products and techniques can drive growth in this market. The market for neurosurgery devices is projected to reach $10 billion by 2029. Elekta's expertise in stereotactic neurosurgery positions it for continued success.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships and acquisitions can expand Elekta's product portfolio and market reach. Collaborating with other medical technology companies and research institutions can accelerate innovation and drive growth. Elekta's financial resources and industry expertise make it an attractive partner for potential acquisitions.
Opportunities
- Expansion of Elekta Unity MR-Linac.
- Growth in software and service revenue.
- Emerging markets expansion.
- Innovation in neurosurgery.
Threats
- Competition from established players.
- Technological obsolescence.
- Regulatory changes.
- Economic downturns.
Competitive Advantages
- Established brand reputation in radiation therapy and neurosurgery.
- Proprietary technology and intellectual property.
- Extensive installed base of equipment.
- Strong relationships with key opinion leaders and medical professionals.
About EKTAY
Elekta AB (publ) was founded in 1972 in Stockholm, Sweden, with the mission of improving patient outcomes through innovative medical technology. Initially focused on neurosurgery, the company pioneered the Leksell Gamma Knife, a device for non-invasive brain surgery. Over the years, Elekta expanded its portfolio to include radiation therapy systems, treatment planning software, and oncology information systems. Today, Elekta offers a comprehensive suite of solutions for cancer and brain disorder treatments, including the Versa HD linear accelerator, Elekta Unity MR-Linac, and MOSAIQ Plaza oncology information system. The company's products are used in hospitals and cancer centers worldwide, serving a global patient population. Elekta faces competition from other medical technology companies in the radiation oncology and neurosurgery markets.
What They Do
- Develops and manufactures radiation therapy systems for cancer treatment.
- Offers neurosurgery products, including the Leksell Gamma Knife.
- Provides treatment planning software and oncology information systems.
- Delivers integrated hardware and software solutions for precision radiation medicine.
- Offers services, including installation, training, and support.
- Focuses on improving patient outcomes through innovative medical technology.
Business Model
- Sells radiation therapy systems and neurosurgery products to hospitals and cancer centers.
- Generates revenue from software licenses and service contracts.
- Provides training and support services to customers.
- Offers financing solutions to facilitate equipment purchases.
Industry Context
Elekta operates in the medical instruments and supplies industry, which is characterized by technological innovation, stringent regulatory requirements, and increasing demand for advanced healthcare solutions. The market for radiation therapy equipment is driven by the rising incidence of cancer and the growing adoption of precision radiation medicine. Elekta competes with companies like ARSUF (Accuray Incorporated) and BOEUF (Brainlab AG) in the radiation oncology and neurosurgery markets. The industry is also influenced by trends such as the integration of artificial intelligence and machine learning in treatment planning and delivery.
Key Customers
- Hospitals and cancer centers
- Radiation oncologists
- Neurosurgeons
- Medical physicists
Financials
Chart & Info
Elekta AB (publ) (EKTAY) stock price: $6.31 (+0.13, +2.02%)
Latest News
-
Analyzing Anteris Technologies Global (NASDAQ:AVR) and Elekta (OTCMKTS:EKTAY)
defenseworld.net · Feb 20, 2026
-
European Growth Stocks With Insider Ownership Up To 20%
Yahoo! Finance: EKTAY News · Feb 16, 2026
-
European Growth Stocks With Insider Ownership Up To 20%
Simply Wall St. · Feb 16, 2026
-
Elekta AB (publ) (EKTAY) Shareholder/Analyst Call Transcript
seekingalpha.com · Jan 30, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EKTAY.
Price Targets
Wall Street price target analysis for EKTAY.
MoonshotScore
What does this score mean?
The MoonshotScore rates EKTAY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Analyzing Anteris Technologies Global (NASDAQ:AVR) and Elekta (OTCMKTS:EKTAY)
European Growth Stocks With Insider Ownership Up To 20%
European Growth Stocks With Insider Ownership Up To 20%
Elekta AB (publ) (EKTAY) Shareholder/Analyst Call Transcript
Leadership: Jakob Just-Bomholt
CEO
Jakob Just-Bomholt serves as the CEO of Elekta AB (publ). His background includes extensive experience in the healthcare and technology sectors. Prior to joining Elekta, he held leadership positions at various multinational companies. His expertise spans strategic planning, business development, and operational management. He is responsible for leading Elekta's global operations and driving the company's growth strategy.
Track Record: Since assuming the role of CEO, Jakob Just-Bomholt has focused on driving innovation and expanding Elekta's market presence. Key milestones under his leadership include the continued development and commercialization of Elekta Unity MR-Linac and the expansion of the company's software and service offerings. He has also emphasized strategic partnerships and acquisitions to accelerate growth.
Elekta AB (publ) ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that are held by a U.S. depositary bank. EKTAY is an ADR, meaning that instead of directly owning shares of Elekta AB (publ) traded on the Stockholm exchange, U.S. investors own receipts representing those shares. This allows U.S. investors to trade in USD during U.S. market hours.
- Home Market Ticker: Nasdaq Stockholm, Sweden
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: EKTA
EKTAY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market. Companies in this tier often have limited financial disclosure and may not meet minimum listing requirements. Trading on the OTC Other tier carries higher risks compared to trading on major exchanges like the NYSE or NASDAQ, due to less stringent regulations and potentially lower liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Lower trading volume and liquidity.
- Wider bid-ask spreads.
- Potential for price volatility.
- Higher risk of fraud or manipulation.
- Verify the company's registration and legal status.
- Obtain and review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal proceedings against the company.
- Established history and track record in the medical technology industry.
- Global presence and distribution network.
- Proprietary technology and intellectual property.
- Partnerships with reputable healthcare institutions.
- Presence of institutional investors.
EKTAY Healthcare Stock FAQ
What does Elekta AB (publ) do?
Elekta AB (publ) is a medical technology company that provides clinical solutions for treating cancer and brain disorders. The company develops and manufactures radiation therapy systems, neurosurgery products, and treatment planning software. Its products are used in hospitals and cancer centers worldwide to deliver precision radiation medicine. Elekta's solutions aim to improve patient outcomes and enhance the efficiency of cancer treatment.
What do analysts say about EKTAY stock?
Analyst coverage of EKTAY stock is limited due to its OTC listing and ADR status. However, analysts generally recognize Elekta's established position in the radiation therapy and neurosurgery markets. Key valuation metrics include the company's market capitalization, dividend yield, and P/E ratio. Growth considerations include the adoption of Elekta Unity MR-Linac and the expansion of software and service revenue. Investors should conduct their own research and consult with a financial advisor before making any investment decisions.
What are the main risks for EKTAY?
The main risks for EKTAY include competition from established players in the radiation therapy and neurosurgery markets, technological obsolescence, regulatory changes, economic downturns, and currency fluctuations. As an OTC stock, EKTAY also faces risks related to limited financial disclosure, lower trading volume, and wider bid-ask spreads. Investors should carefully consider these risks before investing in EKTAY.
What are the key factors to evaluate for EKTAY?
Elekta AB (publ) (EKTAY) currently holds an AI score of 47/100, indicating low score. The stock trades at a P/E of 76.3x, above the S&P 500 average (~20-25x), suggesting high growth expectations. Key strength: Established market position in radiation therapy and neurosurgery.. Primary risk to monitor: Potential: Competition from established players in the radiation therapy and neurosurgery markets.. This is not financial advice.
How frequently does EKTAY data refresh on this page?
EKTAY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven EKTAY's recent stock price performance?
Recent price movement in Elekta AB (publ) (EKTAY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established market position in radiation therapy and neurosurgery.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider EKTAY overvalued or undervalued right now?
Determining whether Elekta AB (publ) (EKTAY) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 76.3. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying EKTAY?
Before investing in Elekta AB (publ) (EKTAY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- OTC market data may be limited or unreliable.